Athira Pharma, Inc. lost $24.70 per diluted share in fiscal year 2025. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Athira Pharma, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$24.70
Ticker history: ATHA became
LONA
(LeonaBio, Inc.) on .
Source SEC Filings (10-K/10-Q)Latest period Q1 FY2026, ended Mar 31, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
ATHA EPS (Diluted) by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Athira Pharma, Inc. lost $24.70 per diluted share in fiscal year 2025.
Athira Pharma, Inc. (ATHA) reported -$1.73 in diluted earnings per share in Q1 2026.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Athira Pharma, Inc. (ATHA) reported on that line in every period on record.